Cotton K, Comer C, Caporali S, Butera A, Gurres S, Capradossi F, D'Alessandro A, Amelio I, Niklison-Chirou MV. Lipidome atlas of p53 mutant variants in pancreatic cancer. Biol Direct. 2025 Apr 11; 20(1):51.

Panja S, Kapoor E, Siddhanta K, Jogdeo CM, Sil D, Khan RI, Kumari N, Ding L, Gendelman HE, Singh AB, Oupick? D. Bioactive polymers as stimulus-responsive anti-metastatic combination agents to treat pancreatic cancer. Biomaterials. 2025 Sep; 320:123255.

Rompen IF, Stoop TF, van Roessel S, van Veldhuisen E, Janssen QP, Alseidi A, Balduzzi A, Balzano G, Berrevoet F, Bonds M, Busch OR, Butturini G, Javed AA, Del Chiaro M, Conlon KC, Falconi M, Frigerio I, Fusai GK, Gagni?re J, Griffin O, Hackert T, Sparrelid E, Halimi A, Labori KJ, Malleo G, Marino MV, Mortensen MB, Nikov A, Lesurtel M, Keck T, Kleeff J, Pand? R, Pfeiffer P, Pietrasz D, Roberts KJ, Sa Cunha A, Salvia R, Strobel O, Tarvainen T, van Laarhoven HWM, Groot Koerkamp B, Loos M, Michalski CW, Besselink MG, Hank T. Validation of the PANAMA Score for Survival and Benefit of Adjuvant Therapy in Patients With Resected Pancreatic Cancer after Neoadjuvant FOLFIRINOX. Ann Surg. 2025 May 01; 281(5):852-860.

Gadwa J, Yu J, Piper M, Knitz MW, Darragh LB, Olimpo N, Corbo S, Beynor JI, Neupert B, Nguyen AT, Hodgson C, Nguyen D, Abdelazeem KN, Saviola A, Pousse L, Bransi A, Pincha M, Klein C, Amann M, Karam SD. Divergent response to radio-immunotherapy is defined by intrinsic features of the tumor microenvironment. J Immunother Cancer. 2025 Jan 07; 13(1).

Andel PCM, van Goor IWJM, Augustinus S, Berrevoet F, Besselink MG, Bhojwani R, Boggi U, Bouwense SAW, Cirkel GA, van Dam JL, Djanani A, Dorcaratto D, Dreyer S, den Dulk M, Frigerio I, Ghorbani P, Goetz MR, Groot Koerkamp B, Gryspeerdt F, Hidalgo Salinas C, Intven M, Izbicki JR, Jorba Martin R, Kauffmann EF, Klug R, Liem MSL, Luyer MDP, Maglione M, Martin-Perez E, Meerdink M, de Meijer VE, Nieuwenhuijs VB, Nikov A, Nunes V, Pando E, Radenkovic D, Roeyen G, Sanchez-Bueno F, Serrablo A, Sparrelid E, Tepetes K, Thakkar RG, Tzimas GN, Verdonk RC, Ten Winkel M, Zerbi A, Groot VP, Molenaar IQ, Daamen LA, van Santvoort HC. Routine Imaging or Symptomatic Follow-Up After Resection of Pancreatic Adenocarcinoma. JAMA Surg. 2025 Jan 01; 160(1):74-84.

Hill CS, Parkinson R, Jaffee EM, Sugar E, Zheng L, Onners B, Weiss MJ, Wolfgang CL, Cameron JL, Pawlik TM, Rosati L, Le DT, Hacker-Prietz A, Lutz ER, Schulick R, Narang AK, Laheru DA, Herman JM. Phase 1 Study of Adjuvant Allogeneic Granulocyte-Macrophage Colony-Stimulating Factor-Transduced Pancreatic Tumor Cell Vaccine, Low-Dose Cyclophosphamide, and Stereotactic Body Radiation Therapy Followed by FOLFIRINOX in High-Risk Resected Pancreatic Ductal Adenocarcinoma. Int J Radiat Oncol Biol Phys. 2025 Mar 15; 121(4):930-941.

Borazanci EH, Bahary N, Chung V, Huyck TK, Kio EA, Chiorean EG, Skeel RT, Alese OB, Cardin DB, Fountzilas C, Hanna WT, Leal AD, Lee V, Noonan AM, Philip PA, Wainberg ZA, Pashova H, Mann G, Oberstein PE. Relacorilant plus nab-paclitaxel for the treatment of metastatic pancreatic ductal adenocarcinoma: results from the open-label RELIANT study. Oncologist. 2024 Nov 04; 29(11):957-965.

Coveler AL, Reilley MJ, Zalupski M, Macarulla T, Fountzilas C, Ponz-Sarvis? M, Nagrial A, Uboha NV, Frentzas S, Overman M, Noonan A, Messersmith WA, Pavlakis N, Mettu NB, Bisha I, Wang Y, Smith P, Murtomaki E, Bielska AA, Bragulat V, Cooper ZA, Kumar R, Spigel DR. A Phase Ib/II Randomized Clinical Trial of Oleclumab with or without Durvalumab plus Chemotherapy in Patients with Metastatic Pancreatic Ductal Adenocarcinoma. Clin Cancer Res. 2024 Oct 15; 30(20):4609-4617.

Habib JR, Kinny-K?ster B, Javed AA, Zelga P, Saadat LV, Kim RC, Gorris M, Allegrini V, Watanabe S, Sharib J, Arcerito M, Kaiser J, Lafaro KJ, Tu M, Bhandre M, Shi C, Kim MP, Correa C, Daamen LA, Oberstein PE, Schmidt CM, Hanna NN, Allen P, Loos M, Shrikhande SV, Molenaar IQ, Frigerio I, Katz MHG, Soares KC, Miao Y, Del Chiaro M, He J, Hackert T, Salvia R, B?chler MW, Castillo CF, Besselink MG, Marchegiani G, Wolfgang CL. Impact of Adjuvant Chemotherapy on Resected Intraductal Papillary Mucinous Neoplasm-Derived Pancreatic Cancer: Results From an International Multicenter Study. J Clin Oncol. 2024 Dec 20; 42(36):4317-4326.

Yee EJ, Torphy RJ, Myers EK, Meguid C, Franklin O, Sugawara T, Franco SR, Clark TJ, Mungo B, Ahrendt SA, Schulick RD, Del Chiaro M, McCarter MM. Dynamic Anthropometrics in Pancreatic Cancer: Associations Between Body Composition Changes During Neoadjuvant Therapy and Survival Outcomes After Resection. Ann Surg Oncol. 2024 Nov; 31(12):8340-8351.